AR055649A1 - Metodo de mejora de la funcion cognitiva - Google Patents
Metodo de mejora de la funcion cognitivaInfo
- Publication number
- AR055649A1 AR055649A1 ARP060104149A ARP060104149A AR055649A1 AR 055649 A1 AR055649 A1 AR 055649A1 AR P060104149 A ARP060104149 A AR P060104149A AR P060104149 A ARP060104149 A AR P060104149A AR 055649 A1 AR055649 A1 AR 055649A1
- Authority
- AR
- Argentina
- Prior art keywords
- cognitive function
- individual
- improvement method
- function improvement
- homozygous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Un método para mejorar la funcion cognitiva en un individuo que padece MCI o enfermedad de Alzheimer, y que no es homocigotico para el alelo APOE4, que compende las etapas de: (i) someter al individuo a cribado para determinar que el individuo no sea homocigotico para el alelo APOE4; y después (ii) administrar una cantidad segura y eficaz de un agonista de PPAR-gamma a dicho individuo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71935305P | 2005-09-22 | 2005-09-22 | |
US72737705P | 2005-10-17 | 2005-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055649A1 true AR055649A1 (es) | 2007-08-29 |
Family
ID=37876831
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104148A AR056527A1 (es) | 2005-09-22 | 2006-09-25 | Composicion farmaceutica para mejorar la funcion cognitiva |
ARP060104149A AR055649A1 (es) | 2005-09-22 | 2006-09-25 | Metodo de mejora de la funcion cognitiva |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104148A AR056527A1 (es) | 2005-09-22 | 2006-09-25 | Composicion farmaceutica para mejorar la funcion cognitiva |
Country Status (16)
Country | Link |
---|---|
US (2) | US20080262047A1 (es) |
EP (2) | EP1926488A2 (es) |
JP (2) | JP2009508960A (es) |
KR (2) | KR20080058413A (es) |
AR (2) | AR056527A1 (es) |
AU (2) | AU2006295010A1 (es) |
BR (2) | BRPI0616100A2 (es) |
CA (2) | CA2623210A1 (es) |
CR (2) | CR9848A (es) |
EA (2) | EA200800880A1 (es) |
IL (2) | IL190224A0 (es) |
MA (2) | MA29871B1 (es) |
NO (2) | NO20081847L (es) |
PE (2) | PE20070618A1 (es) |
TW (2) | TW200803851A (es) |
WO (2) | WO2007038112A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
WO2009043593A1 (en) * | 2007-10-05 | 2009-04-09 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using memantine and glitazones |
EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
US8846315B2 (en) * | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
JP5833922B2 (ja) | 2008-08-12 | 2015-12-16 | ジンファンデル ファーマシューティカルズ インコーポレイテッド | 疾患危険因子を同定する方法 |
WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
EP2445498A1 (en) * | 2009-06-25 | 2012-05-02 | Alcobra Ltd. | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
US20130267560A1 (en) * | 2010-10-22 | 2013-10-10 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
EP2665479B1 (en) | 2011-01-10 | 2019-06-26 | Zinfandel Pharmaceuticals, Inc. | Methods and drug products for treating alzheimer's disease |
BR112013017444A2 (pt) * | 2011-01-10 | 2016-09-27 | Zinfandel Pharmaceuticals Inc | método de determinar o risco para o desenvolvimento da doença de alzheimer em um indivíduo, de tratar um indivíduo para a doença de alzheimer e de determinar um risco para desenvolver a doença de alzheimer em um paciente |
CA2852417A1 (en) | 2011-10-21 | 2013-04-25 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
WO2013063086A1 (en) * | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
WO2014171542A1 (ja) * | 2013-04-19 | 2014-10-23 | 武田薬品工業株式会社 | 放出制御製剤 |
CA3032036A1 (en) * | 2016-07-26 | 2018-02-01 | Ausio Pharmaceuticals, Llc | Methods of diagnosing and treating alzheimer's disease with s-equol |
US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
KR102224918B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2148116T1 (es) * | 1992-10-13 | 2000-10-16 | Univ Duke | Metodos de detectar la enfermedad de alzheimer. |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
JP2002532416A (ja) * | 1998-12-17 | 2002-10-02 | マインドセット・バイオファーマシューティカルズ・(ユーエスエイ)・インコーポレイテッド | 脳のグルコース利用の増進 |
US20070129350A1 (en) * | 2004-01-30 | 2007-06-07 | Axonyx, Inc. | Methods for treatment of diabetes |
-
2006
- 2006-09-20 US US12/067,374 patent/US20080262047A1/en not_active Abandoned
- 2006-09-20 AU AU2006295010A patent/AU2006295010A1/en not_active Abandoned
- 2006-09-20 KR KR1020087009286A patent/KR20080058413A/ko not_active Application Discontinuation
- 2006-09-20 BR BRPI0616100-6A patent/BRPI0616100A2/pt not_active Application Discontinuation
- 2006-09-20 JP JP2008532341A patent/JP2009508960A/ja active Pending
- 2006-09-20 CA CA002623210A patent/CA2623210A1/en not_active Abandoned
- 2006-09-20 BR BRPI0616192-8A patent/BRPI0616192A2/pt not_active Application Discontinuation
- 2006-09-20 AU AU2006295007A patent/AU2006295007A1/en not_active Abandoned
- 2006-09-20 KR KR1020087009295A patent/KR20080056731A/ko not_active Application Discontinuation
- 2006-09-20 EA EA200800880A patent/EA200800880A1/ru unknown
- 2006-09-20 EA EA200800879A patent/EA200800879A1/ru unknown
- 2006-09-20 EP EP06815011A patent/EP1926488A2/en not_active Withdrawn
- 2006-09-20 WO PCT/US2006/036597 patent/WO2007038112A2/en active Application Filing
- 2006-09-20 US US12/067,382 patent/US20080226719A1/en not_active Abandoned
- 2006-09-20 TW TW095134700A patent/TW200803851A/zh unknown
- 2006-09-20 JP JP2008532338A patent/JP2009508959A/ja active Pending
- 2006-09-20 CA CA002623204A patent/CA2623204A1/en not_active Abandoned
- 2006-09-20 TW TW095134699A patent/TW200803896A/zh unknown
- 2006-09-20 EP EP06803887A patent/EP1940403A2/en not_active Withdrawn
- 2006-09-20 WO PCT/US2006/036603 patent/WO2007038115A2/en active Application Filing
- 2006-09-21 PE PE2006001145A patent/PE20070618A1/es not_active Application Discontinuation
- 2006-09-21 PE PE2006001143A patent/PE20070976A1/es not_active Application Discontinuation
- 2006-09-25 AR ARP060104148A patent/AR056527A1/es unknown
- 2006-09-25 AR ARP060104149A patent/AR055649A1/es unknown
-
2008
- 2008-03-17 IL IL190224A patent/IL190224A0/en unknown
- 2008-03-17 IL IL190217A patent/IL190217A0/en unknown
- 2008-03-28 CR CR9848A patent/CR9848A/es not_active Application Discontinuation
- 2008-03-28 CR CR9849A patent/CR9849A/es not_active Application Discontinuation
- 2008-04-15 MA MA30849A patent/MA29871B1/fr unknown
- 2008-04-15 MA MA30850A patent/MA29872B1/fr unknown
- 2008-04-16 NO NO20081847A patent/NO20081847L/no not_active Application Discontinuation
- 2008-04-16 NO NO20081843A patent/NO20081843L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200803896A (en) | 2008-01-16 |
US20080226719A1 (en) | 2008-09-18 |
EP1926488A2 (en) | 2008-06-04 |
NO20081843L (no) | 2008-06-16 |
TW200803851A (en) | 2008-01-16 |
WO2007038112A3 (en) | 2007-12-06 |
CA2623210A1 (en) | 2007-04-05 |
BRPI0616100A2 (pt) | 2011-06-07 |
KR20080056731A (ko) | 2008-06-23 |
KR20080058413A (ko) | 2008-06-25 |
IL190217A0 (en) | 2008-11-03 |
IL190224A0 (en) | 2008-11-03 |
EP1940403A2 (en) | 2008-07-09 |
BRPI0616192A2 (pt) | 2011-06-14 |
WO2007038112A2 (en) | 2007-04-05 |
AU2006295007A1 (en) | 2007-04-05 |
JP2009508959A (ja) | 2009-03-05 |
PE20070618A1 (es) | 2007-07-04 |
CA2623204A1 (en) | 2007-04-05 |
CR9848A (es) | 2008-06-18 |
NO20081847L (no) | 2008-06-18 |
AU2006295010A1 (en) | 2007-04-05 |
CR9849A (es) | 2008-05-21 |
WO2007038115A3 (en) | 2007-12-13 |
US20080262047A1 (en) | 2008-10-23 |
MA29872B1 (fr) | 2008-10-03 |
MA29871B1 (fr) | 2008-10-03 |
EA200800879A1 (ru) | 2008-10-30 |
PE20070976A1 (es) | 2007-12-05 |
AR056527A1 (es) | 2007-10-10 |
WO2007038115A2 (en) | 2007-04-05 |
JP2009508960A (ja) | 2009-03-05 |
EA200800880A1 (ru) | 2009-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055649A1 (es) | Metodo de mejora de la funcion cognitiva | |
AR109995A2 (es) | Método para inhibir la resorción ósea | |
BRPI0516727A (pt) | métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença | |
AR057631A1 (es) | Composiciones y metodos para incrementar la sensibilidad a insulina | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
TW200634006A (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
BR0314690A (pt) | Goma de mascar revestida | |
ATE387194T1 (de) | Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung | |
TW200727090A (en) | Illumination system | |
EA200401365A1 (ru) | Способы лечения илеуса | |
EA200602099A1 (ru) | Получение прегабалина и родственных соединений | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
EA200801942A1 (ru) | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон | |
WO2005050200A3 (en) | Screening assays and methods of tumor treatment | |
UA94922C2 (ru) | Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора | |
EA200401341A1 (ru) | Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания | |
MY151330A (en) | Systems and method for separating proteins from connective tissue | |
TW200639404A (en) | Method of assessing the effectiveness of a treatment regimen | |
NO20043013L (no) | Tetrahydrokinolin analoger som muskarine agonister | |
EA200801297A1 (ru) | Способ снижения уровня постпрандиальной глюкозы | |
WO2009055001A3 (en) | Methods of treating aging and methods of screening candidate agents therefor | |
DE60333901D1 (de) | Verfahren zur reduzierung der angiogenese | |
ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
EP1254260A4 (en) | METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE | |
GB2447373A (en) | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells,pharmaceutical composition including said compounds. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |